keyword
MENU ▼
Read by QxMD icon Read
search

Indacaterol

keyword
https://www.readbyqxmd.com/read/29741108/the-safety-of-indacaterol-for-the-treatment-of-copd
#1
Evgenios I Metaxas, Evangelos Balis
Bronchodilators, namely long-acting inhaled β2-agonists and long-acting muscarinic antagonists, are the first-line medications for chronic obstructive pulmonary disease (COPD). The safety of these medicines is of great concern since COPD patients usually have other co-morbidities such as cardio- and cerebrovascular diseases. Areas covered: In this review we present information about the safety and the use of indacaterol in COPD. Indacaterol is the first once-daily, long-acting inhaled β2-agonist approved for COPD...
May 9, 2018: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/29716881/mini-review-chronic-obstructive-pulmonary-disease-its-new-drug-treatments-and-strategies-a-review
#2
Muhammad Hanif, Junaid Qureshi, Hira Ijaz, Muhammad Iqbal Mustafa, Akhtar Rasul, Naeem Amir, Basma Aftab, Ahad Fayyaz
COPD is a complicated disease. Current available treatments are just for symptomatic relief and they cannot reverse the damages to lungs tissues due to alveolar destruction in COPD. Research is being conducted to evaluate new treatments and strategies to find specific treatments to minimize the symptoms of COPD. A new mixture of herbal medicine i.e AKL1 has emerged and thought to cure COPD symptoms especially cough related quality of life of COPD patients. Although, the results have showed no significant difference as compared to placebo but researchers recommend further evaluation in a large population (COPD Patients) group...
May 2018: Pakistan Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/29713156/indacaterol-glycopyrronium-reduces-the-risk-of-clinically-important-deterioration-after-direct-switch-from-baseline-therapies-in-patients-with-moderate-copd-a-post-hoc-analysis-of-the-crystal-study
#3
Timm Greulich, Konstantinos Kostikas, Mina Gaga, Maryam Aalamian-Mattheis, Nadine S Lossi, Francesco Patalano, Xavier Nunez, Veronica A Pagano, Robert Fogel, Claus F Vogelmeier, Andreas Clemens
Purpose: COPD is a progressive disease characterized by exacerbations and a decline in health status and lung function. Clinically important deterioration (CID) is a composite endpoint used to evaluate treatment efficacy. This analysis evaluated the impact of a direct switch to once-daily indacaterol/glycopyrronium 110/50 µg (IND/GLY) from previous monotherapy with a long-acting β2 -agonist (LABA) or long-acting muscarinic antagonist (LAMA) or with an LABA and an inhaled corticosteroid (LABA + ICS) on reducing CID...
2018: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/29705784/coexisting-heart-failure-and-chronic-obstructive-pulmonary-disease-report-of-two-cases-treated-with-indacaterol-glycopyrronium
#4
Eugenio Roberto Cosentino, Daniela Degli Esposti, Rinaldo Miceli, Crescenzio Bentivenga, Matteo Landolfo, Ilaria Ricci Iamino, Luca Spinardi, Gianluigi Magri, Claudio Borghi
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality worldwide, and it is associated with a high economic burden. Heart failure shares some general symptoms with COPD; thus, diagnosing COPD is difficult in subjects with a history of heart failure, and spi-rometry is mandatory for confirmation. Moreover, COPD is a highly prevalent comorbidity negatively impacting the outcome of heart failure patients. We document here the treatment with indacaterol/glycopyrronium in 2 patients with concomitant COPD and heart failure...
2018: Respiration; International Review of Thoracic Diseases
https://www.readbyqxmd.com/read/29705783/combination-therapy-of-inhaled-indacaterol-glycopyrronium-for-chronic-obstructive-pulmonary-disease-in-the-very-elderly-is-it-safe-an-electrocardiographic-evaluation
#5
Francesco Spannella, Federico Giulietti, Valentina Cesari, Antonio Francioso, Guido Cocci, Laura Landi, Francesca Elena Lombardi, Elisabetta Borioni, Beatrice Bernardi, Giulia Rosettani, Valentina Bordoni, Corrado Iacoacci, Piero Giordano, Riccardo Sarzani
Cardiovascular (CV) comorbidities in patients with chronic obstructive pulmonary disease (COPD) are associated with increased morbidity and mortality, especially in old and very old subjects. The question if long-acting beta-agonist and long-acting muscarinic antagonist could be associated with the increased prevalence of CV-related adverse effects has puzzled, particularly in the past, specialists involved in the management of respiratory diseases. The safety of these compounds has scarcely been tested in patients aged ≥ 65 years with CV comorbidities, since randomized controlled trials rarely include this subpopulation...
2018: Respiration; International Review of Thoracic Diseases
https://www.readbyqxmd.com/read/29705782/indacaterol-glycopyrronium-in-the-treatment-of-severe-respiratory-failure-marked-improvement-of-respiratory-failure-in-a-few-weeks-a-case-report
#6
Riccardo Pistelli, Maria Rosaria Castriotti, Loredana Panico
Chronic obstructive pulmonary disease is a highly prevalent disease, especially in the aging population, associated with several functional disabilities and a high economic burden. Dual bronchodilation with prefixed associations of long-acting β2-agonists and long-acting muscarinic antagonist have a significant role in the management of this condition. The newer combination, indacaterol/glycopyrronium, is useful as a once-a-day therapy and has proven superior to other treatment strategies including inhaled corticosteroids for improving symptoms and clinical condition with a very rapid effect...
2018: Respiration; International Review of Thoracic Diseases
https://www.readbyqxmd.com/read/29705781/the-respiratory-overlap-syndrome-efficacy-and-usefulness-of-the-combined-double-bronchodilation
#7
Albino Petrone, Filippo Luca Fimognari, Francesco Mormile, Leonello Fuso, Michela Quartieri, Ludovico Petrone, Francesco Romano
The coexistence of chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea syndrome in a single patient is known as "overlap syndrome," and worsens the prognosis of the affected subjects. A marked bronchodilation may be useful for the treatment of this condition. In fact, as stated in the GOLD 2017 guidelines, the combination of indacaterol/glycopyrronium may exert positive synergistic effects on smooth muscle cell and airway resistance, with a more pronounced efficiency in reducing lung hyperinflation...
2018: Respiration; International Review of Thoracic Diseases
https://www.readbyqxmd.com/read/29705779/when-two-drugs-are-better-than-three-re-modulating-the-therapeutic-plan-of-a-chronic-obstructive-pulmonary-disease-patient
#8
Antonella Ielpo, Ernesto Crisafulli
We present the case of a 77-year-old man diagnosed with chronic obstructive pulmonary disease (COPD) stage D with emphysema phenotype and treated with triple therapy (salmeterol, fluticasone propionate, and tiotropium) for 1 year without relevant improvements in exertional dyspnea and disease impact. After switching to combination therapy with a long-acting β2-agonist (LABA) and a long-acting muscarinic antagonist (LAMA) (indacaterol/glycopyrronium), we observed, in a 3-month period, a substantial reduction of the modified Medical Research Council (mMRC) dyspnea scale and COPD Assessment Test (CAT) scores...
2018: Respiration; International Review of Thoracic Diseases
https://www.readbyqxmd.com/read/29705778/indacaterol-glycopyrronium-in-clinical-practice-the-italian-experience
#9
Mario Cazzola
No abstract text is available yet for this article.
2018: Respiration; International Review of Thoracic Diseases
https://www.readbyqxmd.com/read/29692607/exacerbation-heterogeneity-in-copd-subgroup-analyses-from-the-flame-study
#10
Claus F Vogelmeier, Kenneth R Chapman, Marc Miravitlles, Nicolas Roche, Jørgen Vestbo, Chau Thach, Donald Banerji, Robert Fogel, Francesco Patalano, Petter Olsson, Konstantinos Kostikas, Jadwiga A Wedzicha
Background: The FLAME study compared once-daily indacaterol/glycopyrronium (IND/GLY) 110/50 μg with twice-daily salmeterol/fluticasone (SFC) 50/500 μg in symptomatic patients with moderate to very severe COPD and a history of exacerbations in the previous year. Methods: This prespecified and post hoc subgroup analysis evaluated treatment efficacy on 1) moderate/severe exacerbations according to prior exacerbation history and treatment, and 2) types of exacerbations according to health care resource utilization (HCRU) during 1-year follow-up...
2018: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/29670344/cost-effectiveness-analysis-of-a-fixed-dose-combination-of-indacaterol-and-glycopyrronium-as-maintenance-treatment-for-copd
#11
Ming-Cheng Chan, Elise Chia-Hui Tan, Ming-Chin Yang
Objective: The aim of this study was to evaluate the cost-effectiveness of the long-acting beta-2 agonist (LABA)/long-acting muscarinic antagonist (LAMA) dual bronchodilator indacaterol/glycopyrronium (IND/GLY) as a maintenance treatment for COPD patients from the perspective of health care payer in Taiwan. Patients and methods: We adopted a patient-level simulation model, which included a cohort of COPD patients aged ≥40 years. The intervention used in the study was the treatment using IND/GLY, and comparators were tiotropium or salmeterol/fluticasone combination (SFC)...
2018: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/29658810/early-changes-in-ediary-copd-symptoms-predict-clinically-relevant-treatment-response-at-12-weeks-analysis-from-the-crystal-study
#12
Konstantinos Kostikas, Maryam Aalamian-Mattheis, Veronica Anna Pagano, Xavier Nunez, Robert Fogel, Francesco Patalano, Andreas Clemens
Early detection of treatment response is important in the long-term treatment and management of patients with chronic obstructive pulmonary disease (COPD). This analysis evaluated whether early improvement in symptoms, recorded in the first 7 or 14 days via an electronic diary (eDiary) compared with baseline, can predict clinically meaningful treatment responders at 12 weeks. CRYSTAL was a 12-week, randomized, open-label study that demonstrated the increased effectiveness of indacaterol/glycopyrronium (IND/GLY) or glycopyrronium (GLY), after a direct switch from on-going baseline therapies, in patients with symptomatic COPD and moderate airflow obstruction...
April 16, 2018: COPD
https://www.readbyqxmd.com/read/29625777/tai-chi-and-pulmonary-rehabilitation-compared-for-treatment-naive-patients-with-copd-a-randomized-controlled-trial
#13
Michael I Polkey, Zhi-Hui Qiu, Lian Zhou, Meng-Duo Zhu, Ying-Xin Wu, Yong-Yi Chen, Sheng-Peng Ye, Yu-Shan He, Mei Jiang, Bai-Ting He, Bhavin Mehta, Nan-Shan Zhong, Yuan-Ming Luo
BACKGROUND: In COPD, functional status is improved by pulmonary rehabilitation (PR) but requires specific facilities. Tai Chi, which combines psychological treatment and physical exercise and requires no special equipment, is widely practiced in China and is becoming increasingly popular in the rest of the world. We hypothesized that Tai Chi is equivalent (ie, difference less than ±4 St. George's Respiratory Questionnaire [SGRQ] points) to PR. METHODS: A total of 120 patients (mean FEV1 , 1...
March 28, 2018: Chest
https://www.readbyqxmd.com/read/29567256/a-validated-capillary-electrophoretic-method-for-the-determination-of-indacaterol-and-its-application-to-a-pharmaceutical-preparation
#14
Tufan Güray, Muzaffer Tunçel, Ulku Dilek Uysal
Indacaterol is a new inhaled ultra-long acting β2 -agonist. It has been recently approved in the European Union for the treatment of chronic obstructive pulmonary disease. This paper reports, for the first time, a method for the determination and validation of Indacaterol (IND) using an internal standard in capsules. Capillary electrophoretic separation was performed on an uncoated fused-silica capillary (50 cm effective length, 75 μm i.d.) and background electrolyte composed of 20 mmol L-1 of sodium tetraborate buffer, 15% (v/v) methanol (pH = 10...
April 2018: Journal of Food and Drug Analysis
https://www.readbyqxmd.com/read/29546433/cost-effectiveness-of-indacaterol-glycopyrronium-in-comparison-with-salmeterol-fluticasone-combination-for-patients-with-moderate-to-severe-chronic-obstructive-pulmonary-disease-a-lantern-population-analysis-from-singapore
#15
Augustine Tee, Wai Leng Chow, Colin Burke, Guruprasad Basavarajaiah
INTRODUCTION: In light of the growing evidence base for better clinical results with the use of the dual bronchodilator indacaterol/glycopyrronium (IND/GLY) over inhaled corticosteroid-containing salmeterol/fluticasone combination (SFC), this study aimed to evaluate the cost-effectiveness of IND/GLY over SFC in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) who are at low risk of exacerbations in the Singapore healthcare setting. METHODS: A previously published patient-level simulation model was adapted for use in Singapore by applying local unit costs...
March 16, 2018: Singapore Medical Journal
https://www.readbyqxmd.com/read/29477448/effect-of-lung-deflation-with-indacaterol-plus-glycopyrronium-on-ventricular-filling-in-patients-with-hyperinflation-and-copd-claim-a-double-blind-randomised-crossover-placebo-controlled-single-centre-trial
#16
Jens M Hohlfeld, Jens Vogel-Claussen, Heike Biller, Dominik Berliner, Korbinian Berschneider, Hanns-Christian Tillmann, Simone Hiltl, Johann Bauersachs, Tobias Welte
BACKGROUND: Pulmonary hyperinflation in chronic obstructive pulmonary disease (COPD) is associated with reduced biventricular end-diastolic volumes and increased morbidity and mortality. The combination of a long-acting β agonist (LABA) and a muscarinic antagonist (LAMA) is more effective in reducing hyperinflation than LABA-inhaled corticosteroid combination therapy but whether dual bronchodilation improves cardiac function is unknown. METHODS: We did a double-blind, randomised, two-period crossover, placebo-controlled, single-centre study (CLAIM) at the Fraunhofer Institute of Toxicology and Experimental Medicine (Hannover, Germany), a specialty clinic...
May 2018: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/29429593/extrafine-inhaled-triple-therapy-versus-dual-bronchodilator-therapy-in-chronic-obstructive-pulmonary-disease-tribute-a-double-blind-parallel-group-randomised-controlled-trial
#17
Alberto Papi, Jørgen Vestbo, Leonardo Fabbri, Massimo Corradi, Hélène Prunier, Géraldine Cohuet, Alessandro Guasconi, Isabella Montagna, Stefano Vezzoli, Stefano Petruzzelli, Mario Scuri, Nicolas Roche, Dave Singh
BACKGROUND: Evidence is scarce on the relative risk-benefit of inhaled triple therapy, consisting of inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting β2 -agonist, versus dual bronchodilation for chronic obstructive pulmonary disease (COPD). We aimed to compare a single-inhaler triple combination of beclometasone dipropionate, formoterol fumarate, and glycopyrronium (BDP/FF/G) versus a single-inhaler dual bronchodilator combination of indacaterol plus glycopyrronium (IND/GLY) in terms of the rate of moderate-to-severe COPD exacerbations over 52 weeks of treatment...
March 17, 2018: Lancet
https://www.readbyqxmd.com/read/29317812/the-impact-of-indacaterol-glycopyrronium-fixed-dose-combination-versus-tiotropium-monotherapy-on-lung-function-and-treatment-preference-a-randomized-crossover-study-the-favor-study
#18
Peter Kardos, Ina Hagedorn-Peinz
Background: The objective of the FAVOR study was to evaluate the effect of indacaterol/glycopyrronium (IND/GLY) versus tiotropium on peak forced expiratory volume in 1 s (FEV1 ) and also to investigate patient satisfaction and treatment preference. Methods: Patients with moderate-to-severe airflow limitation (FEV1 /forced vital capacity ratio of <0.70), those with a COPD assessment test score of ≥10, and those who were maintained on tiotropium HandiHaler® therapy prior to enrollment were recruited for the study, and randomized (1:1) to receive either 4 weeks open-label IND/GLY (110/50 μg) once daily followed by 4 weeks of tiotropium (18 μg) once daily or vice versa...
2018: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/29238696/identification-of-clinically-approved-drugs-indacaterol-and-canagliflozin-for-repurposing-to-treat-epidermal-growth-factor-tyrosine-kinase-inhibitor-resistant-lung-cancer
#19
Hongjian Li, Christy Wing-Sum Tong, Yee Leung, Man-Hon Wong, Kenneth Kin-Wah To, Kwong-Sak Leung
In advanced lung cancer, epidermal growth factor tyrosine kinase inhibitors (EGFR TKIs) have extraordinary clinical efficacy. However, their usefulness is severely compromised by drug resistance mediated by various mechanisms, the most important of which is the secondary EGFR T790M mutation. The mutation blocks the binding of EGFR TKIs to the receptor kinase, thereby abolishing the therapeutic efficacy. In this study, we used our free and open-source protein-ligand docking software idock to screen worldwide approved small-molecule drugs against EGFR T790M...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/29228950/indacaterol-glycopyrronium-is-cost-effective-compared-to-salmeterol-fluticasone-in-copd-flame-based-modelling-in-a-swedish-population
#20
Leif Bjermer, Job F M van Boven, Madlaina Costa-Scharplatz, Dorothy L Keininger, Florian S Gutzwiller, Karin Lisspers, Ronan Mahon, Petter Olsson, Nicolas Roche
BACKGROUND: This study assessed the cost-effectiveness of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC) in chronic obstructive pulmonary disease (COPD) patients with moderate to very severe airflow limitation and ≥1 exacerbation in the preceding year. METHODS: A previously published and validated patient-level simulation model was adapted using clinical data from the FLAME trial and real-world cost data from the ARCTIC study. Costs (total monetary costs comprising drug, maintenance, exacerbation, and pneumonia costs) and health outcomes (life-years (LYs), quality-adjusted life-years (QALYs)) were projected over various time horizons (1, 5, 10 years, and lifetime) from the Swedish payer's perspective and were discounted at 3% annually...
December 11, 2017: Respiratory Research
keyword
keyword
38795
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"